Diagnosing hyperglycemia (GDM) in pregnancy: closing the door after the horse has bolted?

Chittaranjan S. Yajnik, Souvik Bandyopadhyay, Dattatray S. Bhat, Rucha H. Wagh, Pallavi C. Yajnik, Rasika Ladkat, Kurus Coyaji, Clive Osmond and Caroline H.D. Fall

Affiliations

Chittaranjan S Yajnik, MD Diabetes Unit, KEM Hospital Research Centre, Pune, India

Souvik Bandyopadhyay, PhD. Cytel, Inc., Cambridge, MA, USA

Dattatray S Bhat, MSc. Diabetes Unit, KEM Hospital Research Centre, Pune, India

Rucha H Wagh, MSc. Diabetes Unit, KEM Hospital Research Centre, Pune, India

Pallavi C Yajnik, MCom. Diabetes Unit, KEM Hospital Research Centre, Pune, India

Rasika Ladkat, M.A. Diabetes Unit, KEM Hospital Research Centre, Pune, India

Kurus Coyaji, MD. Diabetes Unit, KEM Hospital Research Centre, Pune, India

Clive Osmond, PhD. MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

Caroline HD Fall, DM. MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

Corresponding author

Professor Chittaranjan S Yajnik
Director, Diabetes Unit
KEM Hospital Research centre
Pune, India
csyajnik@gmail.com; +91 98228 47481

Correspondence

Word counts
Abstract 258
Main text 3141
Figures: 4, tables: 1

Abstract

Introduction: Gestational diabetes (GDM) increases risk of diabetes and obesity (diabesity) in the offspring. However, intensive treatment of GDM (generally diagnosed late in pregnancy) has failed to reduce these outcomes in RCTs. The vital window for programming of diabesity is pre- and peri-conceptional, and is influenced by maternal metabolism. Though it is known that metabolic-endocrine abnormalities of 'GDM' may be detectable before pregnancy, there is little data on the life course precursors of pregnancy hyperglycemia.

Methods: The Pune Maternal Nutrition Study birth cohort was set up in 1993-96. 171/366 females born in the study had married and delivered a baby by Feb 2020. We have serial glycemic and body size data for these women at age 6, 12 and 18y, in pregnancy, and post-delivery.

Results: At 28-wks gestation the mothers were 21y old, their median BMI 22 kg/m^2, and twenty had GDM (IADPSG). Given the small number of GDM, we called the 4th quartile of FPG ($\geq$4.7 mmol/l, N=44) 'fasting hyperglycemic' and compared the serial fasting plasma glucose (FPG) of these with the remaining 126 ('normoglycemic'). Women with fasting hyperglycemia had higher FPG at 6, 12 and 18-years and post-delivery, and higher HbA1c before pregnancy. Women with fasting hyperglycemia were thin as a group, but they had higher BMI and waist circumference throughout compared to normoglycemic.

Interpretation: Pregnancy glycemia reflects glycemia throughout childhood and adolescence. Diagnosing *GDM* in pregnancy ignores exposure of the ovum and the embryo to an abnormal metabolic milieu and fails to influence the periconceptional programming of diabesity. Diagnosing and treating GDM in late pregnancy will not curtail the escalating epidemic of diabesity in the young.

Keywords: GDM, gestational fasting hyperglycemia, lifecourse evolution

Funding: The PMNS was funded by the Wellcome Trust, UK (038128/Z/93, 059609/Z/99, 079877/Z/06/Z, 098575/B/12/Z and 083460/Z/07/Z), MRC, UK (MR/J000094/1) and Department of Biotechnology, GoI (BT/PR-6870/PID/20/268/2005). The PRIYA trial is funded by the Indian Council of Medical Research (58/1/8/MRC-ICMR/2009/NCD-II) and Medical Research Council, UK (MR/J000094/1) as part of an Indo-UK collaborative call. The biological sample collection and analysis was funded by the DBT-CEIB grant (BT/PR12629/MED/97/364/2016). Between these grants, the study was funded intramurally (KEMHRC).

Research in context

Evidence before this study:

Most clinicians and researchers believe that 'gestational' diabetes comes during pregnancy and goes away after delivery. The current practice is to diagnose GDM by an OGTT between 24-28 weeks though some suggest earlier diagnosis (at booking visit), especially in those at higher risk. Several studies, either by design or access to previous opportunistic investigation have reported higher glucose, HbA1c, lipids, and BMI years before diagnosis of GDM. A few cohorts have also reported higher glucose and HbA1c before pregnancy in those subsequently diagnosed with GDM. These markers have mostly been classified as 'risk factors' for GDM, without considering the possibility that a disorder was already present before pregnancy. On the other hand, a few epidemiologists have asserted that GDM is pre-gestational but this has not been much acknowledged and has not influenced clinical practice.

Maternal hyperglycemia adversely influences pregnancy outcomes, and increases long-term risk of diabetes and obesity in the offspring (as well as in the mother). Randomised controlled trials of intensive glycemic control in pregnancy (usually initiated in the third trimester, sometimes earlier) prevent some of the short-term pregnancy outcomes but not the long-term risk of diabetes and obesity in the offspring. This may be due to genetic transmission but more likely due to pre- and peri-conceptional 'epigenetic programming'. Programming is influenced by the metabolic milieu of the ova and the conceptus which includes maternal metabolites, nutrients etc. This crucial period is systematically missed in the current clinical management of GDM

Our literature search revealed no study which has reported the life-course evolution of pregnancy glycemia which will have a bearing on the pre- and periconceptional programming of diabetes in the offspring.

Added value of this study:

We describe for the first time a life course trajectory of glycemia in women born in a rural preconceptional birth cohort in India 30 years ago, followed throughout childhood and adolescence, marriage and pregnancy and developed gestational fasting hyperglycemia. We start with their exposure to maternal glycemia during intrauterine life, and track their consistently elevated glycemic curve from childhood into puberty, young adulthood, pregnancy, and post-pregnancy compared to that of women with 'normal' pregnancy glycemia. This demonstrates that the hyperglycemic women's ova and conceptus would be exposed to higher glucose concentrations and that hyperglycemia in pregnancy is only a window in the life course and not a *de novo* phenomenon. The glycemic separation between the two groups was exaggerated during the post-delivery follow-up, pushing these women towards type 2 diabetes.

Implications of all the available evidence:

We provide proof that gestational hyperglycemia (GDM) is not only 'gestational' but is a continuation of elevated glycemia from early life. This has implications not only for the diagnosis and treatment of 'GDM' to improve pregnancy outcomes but especially for the

primordial prevention of the intergenerational programming of the diabetes epidemic. Our results suggest that hyperglycemia in young women should be diagnosed and controlled before pregnancy to curtail pre- and peri-conceptional programming of diabetes. This will shift the focus from the clinic to the community, from clinical medicine to public health. Further research will define the role of genetic and epigenetic factors involved.

Introduction

In 2021, the IDF estimated that every year 21.1 million babies (~17% of live births) in the world are born in a 'hyperglycemic' pregnancy, and an overwhelming majority of these are first discovered only during pregnancy, so-called gestational diabetes (GDM)[1]. The majority of GDM cases were in the low-and middle-income countries (LMICs). Current standards of practice recommend diagnosing GDM between 24-28 weeks of gestation. In addition to adverse pregnancy outcomes involving both the mother and the baby, GDM is thought to be a precursor to diabetes and cardiovascular disease (CVD), both in the mother and the child[2,3]. RCTs of intensive treatment of GDM have shown a reduction in the incidence of LGA/macrosomia and associated obstetric problems but have failed to protect the offspring against childhood obesity and glucose intolerance[3-6]. This could be ascribed to genetic transmission and/or to fetal epigenetic programming of these conditions.

Clinicians and patients usually believe that GDM is a transitory phenomenon due to the endocrine-metabolic stress of pregnancy and will resolve after the delivery of the child. There is increasing evidence that the characteristic abnormalities of GDM (hyperglycemia, low insulin secretion, and insulin resistance) precede pregnancy. This was reported in the pioneering serial metabolic studies before and during pregnancy by Prof Catalano, in clinic-based data in California (USA)[7], in the CARDIA (USA)[8] and MUSP (Australia) cohorts[9], in the Cardiovascular Risk in Young Finns Study[10], and a population-based study in Ontario Canada[11]. However, we could not find any reports in the literature of a life course trajectory of glycemic measurements starting *in-utero*, and serially in postnatal life (early childhood into adult age) in women later developing pregnancy hyperglycemia.

The Pune Maternal Nutrition Study is a pre-conceptional birth cohort in six villages near Pune, India, with a 30-year follow-up since its inception in 1993[12,13]. Data is available on 3 successive generations (F0, F1, F2). Serial measurements of body size and glucose-insulin metabolism are available in the female offspring (F1) from childhood, through puberty and adolescence, to their first pregnancy and after delivery. Maternal (F0) pregnancy glucose tolerance information is also available. This provided us with a unique opportunity to construct a life course trajectory of maternal pregnancy glycemia (F1). We tested the hypothesis that 'gestational' diabetes is not of de-novo gestational origin but originates in early life (fetal life and childhood). This may help assess the appropriateness of the current clinical practice of diagnosing and treating GDM in pregnancy, and its implications for intergenerational transfer of risk of diabesity.

Methods

Overview of the PMNS cohort

The PMNS was established in 1993 in six villages near Pune, India to study associations of maternal nutrition with fetal growth and to study life-course trajectories of growth and cardio-metabolic risk factors in the offspring (Figure 1)[12].

F0 generation

Briefly, married, non-pregnant women (N=2,466) were followed regularly for menstrual history and body size measurements. They were recruited into the main study when a singleton pregnancy of <21 weeks' gestation was confirmed by ultrasound. Maternal medical, nutritional, and biochemical information was obtained at 18- and 28-weeks' gestation, including a 75gm fasting OGTT at 28-weeks. Deliveries happened at home or local health centers[12]. Mother and father underwent cardiometabolic assessment 6,12 and 24 years after delivery. The socioeconomic status of the families was assessed by a standard method (Standard of Living Index, NFHS-2)[12].

Lifecourse measurements of F1 generation

Birth to 18-years

Anthropometric measurements were made using standardized protocols at birth and during subsequent follow-ups (ESM table S1)[12]. At age 6 years, a 1.75g/kg oral glucose tolerance test (OGTT; fasting, 30 min, and 120 min venous blood samples), and at 18 years a 75g OGTT were performed. At 12 years, only a fasting blood sample was collected. Plasma glucose was measured by GOD-POD method on automated system, within and between batch CV was <3%. HbA1c was measured on Bio-Rad D10 system (Cation exchange) between 15- and 17-years of age.

Pregnancy

Marriage and pregnancy were recorded by the field staff. Gestational weight gain was calculated between 18y and 28-wks gestation. At 28 weeks' gestation a fasting OGTT (75g anhydrous glucose) was performed. Samples were collected fasting, and 60- and 120 mins after the glucose load. Gestational diabetes (GDM) was diagnosed by the IADPSG criteria and appropriately treated (https://www.iadpsg.org/, accessed on 1 Jan 2024). Pregnancy and delivery outcomes were recorded. Neonatal anthropometry (F2) was performed using standardized methods[13].

Post-delivery follow-up

At ~24 years of age, F1 women underwent anthropometric measurements and a 75gm OGTT. This activity was halted due to the COVID pandemic between Mar 2020 to Mar 2022, and resumed subsequently. F0 parents were also followed-up as previously. We used data collected till January 2024 for this analysis.

Definitions

In F0 mothers, GDM was diagnosed by WHO 1985 criteria (75gm fasting OGTT)[14]. In F1 generation, GDM was diagnosed by IADPSG criteria (https://www.iadpsg.org/, accessed on 1 Jan 2024). Given the small number of GDM cases (n=20/158, 12.5%), we defined 'fasting hyperglycemia' in F1 mothers as highest quartile (Q4, $\geq$ 4.7 mmol/l) of fasting plasma glucose (FPG) concentrations and Q1+Q2+Q3 as 'normoglycemia'. The glycemic status in non-pregnant adults (F0 parents, and F1 daughters at 18- and 24-years of age) was classified as per ADA criteria (https://diabetes.org/about-diabetes/diagnosis, accessed on 1 Jan 2024). 'Ever glucose intolerant' mothers refers to presence of prediabetes or diabetes at point in the lifecourse.

Statistical analysis

Our main analysis is to compare the life-course evolution of glycemia and body size measurements in women (F1) with and without fasting hyperglycemia at 28-wks gestation (Table 1). Variables with skewed distributions were normalized by appropriate transformation. All variables were converted to z-scores, and differences between normoglycemic and fasting hyperglycemic participants were expressed in z-score units with 95% CIs and tested using t-test statistics. The lifecourse evolution of fasting glycemia and size measurements is shown as serial line plots (point estimates, medians) for those with fasting hyperglycemia and normoglycemia during pregnancy (Figure 2).

We calculated odds ratios to estimate the risk of having fasting hyperglycemia at 28-wks gestation for Q4 of FPG at 6-, 12-, and 18-years. Similarly, we estimated the risk of being glucose intolerant (prediabetes+diabetes) at 24-years for Q4 of FPG at 6-, 12-, 18-years and 28-wks gestation. The odds ratios are represented using forest plots.

All the statistical analysis was performed using SPSS v26 and R 4.0.5 softwares.

Ethics

The study was approved by village leaders and the KEM Hospital Research Centre Ethics Committee (Pune, India) at all timepoints. Participants >18 years of age signed an informed consent. Children <18 years of age provided assent along with parental consent.

Results

Description of study (figure 1, ESM figure S1)

In the PMNS, data is available on F0 mothers during pregnancy (1993-96), including sociodemographic, anthropometric, FPG (n=683), and a 75g fasting OGTT (n=598) at 28-weeks' gestation. They were 21.2 years old, 1.52 m tall, had a median BMI of 20.2 kg/m^2, a third were primiparous, and only 3/598 (<1%) were diagnosed with GDM[14].

Three hundred and sixty-six live singleton F1 female offspring were born (and 396 males). By February 2020 when data collection was stopped due to the COVID pandemic, 223 of these women had married, and 195 had become pregnant and delivered. The analysis includes 171 women on whom FPG measurements were available at 28-wk of gestation, 158 also had OGTT data. These women were similar to those not included in this analysis, for their birthweight, BMI, and FPG at 6, 12, and 18y (ESM table S1). They were 20.9 years old, had a median BMI of 21.7 kg/m^2 (20.0, 23.8), and all were primiparous. One hundred and thirty-six of these women also attended a post-delivery follow-up at an average age of 24.3 years (2019-24) for cardiometabolic measurements including a 75g OGTT.

Distribution of glucose concentration at 28-wk gestation in the F1

FPG concentrations ranged (min-max) from 3.3 – 6.5 mmol/l, 60-mins glucose 3.9 – 11.4 mmol/l and 120-min 3.4 – 9.9 mmol/l. Twenty (12.6%) could be classified as GDM (IADPSG criteria): 11 had FPG ≥5.1 mmol/l , 10 had 60-min ≥ 9.99 mmol/l , and 4 had 120-min≥ 8.49 mmol/l. Given the small number of GDM, we preferred to classify women above the 4th quartile of FPG (Q4, >=4.7 mmol/l, n=44) as 'fasting hyperglycemia' and Q1+Q2+Q3 (N=127) as 'normoglycemia', to increase the power of analysis and in the knowledge that FPG is a more significant predictor of pregnancy outcomes[15].

Comparison between F1 women with gestational fasting hyperglycemia and normoglycemia (Table 1)

Women in the two glycemic groups had similar height and gestational weight gain (8.9 vs 8.9 kg) but those with hyperglycemia were older, and had a higher BMI (median 23.3 vs 21.2 kg/m^2) compared to those with normoglycemia. They had higher glycemia at 60- (7.91 vs 7.49 mmol/L) and 120-mins (6.58 vs 6.22 mmol/L) (Table 1).

Lifecourse tracking of anthropometry and glycemia in F1 women (Table 1, figure 2, ESM figure S2)

We have plotted serial life-course FPG measurements in the hyperglycemic and normoglycemic women in Figure 2. Mean differences in Z-scores between the two glycemic groups have also been shown (ESM figures S2)

At birth, the two glycemic groups (F1) had similar anthropometric measurements (weight, length, abdominal circumference, skinfolds). Women with fasting hyperglycemia were taller at 2 and 6 years and had higher weight, BMI, and larger waist circumference as children, adolescents, and adults (ESM fig S2a). Sum of skinfolds was similar in the two groups throughout. Notably, the BMI of these women was quite low during childhood and

adolescence, at 18 years of age, 34% of women with hyperglycemia were underweight (BMI < 18.5 kg/m2), only 7% has a BMI greater than 25 kg/m^2.

Mothers (F0) of the two glycemic groups of F1 daughters had similar FPG concentration in pregnancy, but a higher proportion of mothers of the hyperglycemic group were ever glucose intolerant. Women (F1) with fasting hyperglycemia in pregnancy had higher FPG concentrations at 6, 12 and 18 years of age compared to those in women with normoglycemia. However, 30- and 120-min plasma glucose concentrations were similar at 6 and 18 years. The prevalence of IFG at 12 years (4.5% vs 0.8%) and 18 years (15% vs 4.9%) was higher in women with fasting hyperglycemia, and they also had higher HbA1c concentrations at 15-17y of age (mean diff +0.40 SD, $p < 0.07$).

Change in glycemia between pre-pregnancy and pregnancy

There was a fall in FPG concentrations during pregnancy from pre-pregnancy concentrations (Table 1); the fall was smaller in women with fasting hyperglycemia compared to those with normoglycemia.

Post-delivery changes (figure 2, ESM fig S2)

Women with gestational fasting hyperglycemia continued to have higher BMI, larger waist circumference, and higher FPG after delivery (age 24 years), the differences between groups widened after delivery.

Predictive ability of early life FPG for gestational fasting hyperglycemia (Figure 3 & 4)

Figures 3a, 3b, 3c show that higher FPG concentrations at 6- 12 and 18 years predicted a consistently higher risk of having gestational fasting hyperglycemia. Higher FPG concentrations at 28-wks gestation, similarly predicted a higher risk of glucose intolerance (prediabetes + diabetes) at 24-years of age, with a steeper gradient (fig 3d). Figure 4 shows forest plots of these associations: for gestational fasting hyperglycemia, the cumulative risk of higher FPG at 6-, 12-, and 18-years was 2.22 (1.45-3.38) (fig 4); for glucose intolerance at 24-years, the cumulative risk of higher FPG at 6-, 12- and 18-years, and 28-wks gestation was 5.22 (2.40-11.33) (fig 4).

Discussion

We provide unique data to show life-course tracking of glycemia in female participants (F1) born in the Pune Maternal Nutrition Study. We trace their glycemia from early childhood and puberty, into early adulthood, pregnancy, and the post-delivery period. Our data highlights that pregnancy glycemia is only a window in the life-course glycemic trajectory. To the best of our knowledge, this is the first demonstration of such tracking. Our previous finding that offspring's glycemia at 18 years of age was significantly correlated with maternal pregnancy glycemia suggests that the tracking indeed extends inter-generationally. These findings challenge the popular belief about 'gestational' diabetes originating in pregnancy and have important implications for the diagnosis, treatment, and follow-up of this condition.

The majority of reports in the literature highlight the increased risk of post-pregnancy diabetes in GDM women. Only a few studies have investigated glucose metabolism in the pre-pregnancy period, usually extending a few months to a few years before pregnancy, none in a lifecourse model. Catalano's classic studies of 38 women in the USA before and in early and late pregnancy showed that women diagnosed with gestational diabetes (GDM) in pregnancy had higher glycemia and lower insulin sensitivity before pregnancy and maintained their differences from the non-GDM women in early and late pregnancy[7]. A clinical report from the Kaiser Permanente system in California showed that women diagnosed with GDM had higher BMI, higher glycemia, and dyslipidemia during an earlier medical examination, compared to women with normal glucose tolerance[16]. Women diagnosed with GDM in the CARDIA cohort in the USA[8], the Cardiovascular Risk in Young Finns Study[10], and MUSP cohort of aboriginal women, Australia[9], all had higher glycemia (glucose, HbA1c) before pregnancy. A recent demonstration of higher HbA1c values in early pregnancy in those who were diagnosed with GDM later in the pregnancy strongly suggest higher glycemia before pregnancy[17]. Data from population-based administrative databases in Ontario, Canada showed that women diagnosed with GDM during pregnancy already had elevated levels of fasting and random glucose, HbA1c, and dyslipidemia a few years before pregnancy, and the glycemic variables showed a faster deterioration after delivery[11,18]. None of these studies have early childhood and intergenerational measurements. In addition, many studies (Bogalusa Heart Study[19], the Early Bird study[20], and i3C[21]) have demonstrated tracking of glycemia from early life into young adulthood but have not extended data collection into pregnancy. We have also described life-course tracking of glycemia in the PMNS and two other Pune birth cohorts (Pune Children's Study, and the Extended PMNS)[12] from childhood to young adulthood.

Our findings have the potential to change clinical thinking and public health practice. Despite the demonstration that the 'characteristic' features of GDM women that distinguish them from women without GDM (higher age, family history of diabetes, overweight-obesity, glucose intolerance, dyslipidaemias, and insulin resistance) exist from before pregnancy, there is a tendency to consider these only as 'risk factors' and not as an existing disease condition, based on arbitrary cut-points. A host of 'biomarkers' in early pregnancy have similarly been proposed to 'predict' later GDM without the appreciation that they represent pre-existing deranged metabolism[22]. Similarly, several 'prevention' trials starting in early

pregnancy or preconceptionally fail to appreciate that it is only secondary prevention (early diagnosis and treatment) and not primary prevention as proposed[23-25].

Our findings have important implications for the timing of diagnosis of hyperglycemia relevant to intergenerational programming of diabetes in the offspring. The current practice of diagnosing and treating GDM in the third trimester has contributed to reducing the incidence of large-for-gestational-age and related perinatal complications but does not reduce the long-term outcomes of diabetes and obesity in the offspring[4,6]. These may be due to genetic transmission from mother to offspring . However, a more important reason may be the epigenetic programming and transmission of susceptibility of diabetes that occurs around gastrulation[26]. This process is over much before GDM is diagnosed and treated. If the woman has higher glucose ('dysglycemia') throughout her life cycle, then her ova will also have altered epigenetic signatures before conception and the periconceptional reprogramming will also occur in an altered metabolic milieu. This has been shown in human and animal studies to increase the risk of diabetes in the offspring[27]. It is also relevant that epigenetic changes (DNA methylation) in the pancreatic islets of islet donors who had mildly elevated glucose concentrations (lower than 'diabetes'), predisposed the recipients to future diabetes[28]. Both these studies strongly support the thesis that lifecourse of mild hyperglycemia in women with 'GDM' will have already altered the 'epigenetic profile' of the offspring before diagnosis and contribute to future risk of diabesity. Wolpert had said "It is not birth, marriage or death, but gastrulation which is truly the most important time in your life"[29].

The time to act to avoid developmental programming of diabetes and obesity is preconceptional[26,30]. This shifts the attention from the clinic to the community, from clinical practice to public health. Diagnosing and improving risk factors for intergenerational programming of diabesity in young children and adolescents qualifies as 'primordial' prevention to help the next generation. This will need cooperation between the medical profession, parents, schools, and governmental and non-governmental agencies to promote health literacy/education. This invites considerable efforts from the health system and expects a change in human behaviour. This is different from targeting high risk individuals in 'primary' prevention. Geoffrey Rose highlighted the larger benefits of intervening to favourably shift the curve rather than concentrating on the tail-end of the distribution[31]. The same thinking underlies recommendations for pre-conceptional folic acid (to women desiring pregnancy, and flour fortification for community) to prevent neural tube defects, and the success of this intervention indicates that pre-conceptional interventions can be acceptable.

Our study has many strengths and a few limitations. We believe that we have perhaps the best data on serial metabolic and anthropometric measurements from childhood to pregnancy and post-pregnancy period, spanning 30 years. This allowed us to construct a trajectory which was not possible until now. We have high rates of follow-up which increases the reliability of our findings. We used standardised methods for all measurements. Our choice of fasting glycemia to represent gestational glucose status is based on many considerations: 1) FPG has the highest day-to-day stability, 2) FPG was much more predictive of pregnancy outcomes than post-glucose values in the HAPO study, 3) it is not affected by differing criteria for diagnosis of glucose intolerance in and outside pregnancy, and 4) the characteristic metabolic abnormality in Indians is in the fasting rather than post-challenge state. Our study may be

looked upon as a relatively 'small' study. However, the findings are clear-cut and relevant for India as well as other populations in the LMICs. It has also to be appreciated that such intensive, long-term community-based follow-ups are difficult to do. The generalisability of our findings to more obese populations may need to be confirmed; however, available data (discussed above) shows that the biology of these associations appears universal.

In summary, we report novel data showing lifecourse tracking of FPG in women with gestational fasting hyperglycemia. It is apparent that gestational glycemia is only a window in the life-course evolution of metabolism. What we diagnose as 'GDM' starts in early life and continues after delivery, it's not a *de novo* disorder of pregnancy[32]. John Jarrett aptly commented that 'gestational diabetes is simply impaired glucose tolerance temporally associated with pregnancy'[33]. Maureen Harris also commented similarly[34]. Our findings have implications for pre- and periconceptional epigenetic programming of diabetes and obesity in the offspring which goes unattended in the current practice of diagnosing GDM in pregnancy (even at the booking visit)[35]. A life-course 'primordial' approach to improve metabolic health of females from early life will be necessary to curtail the epidemic of diabesity in their offspring.

References

1. Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, Hoegfeldt CA, Powe CE, Immanuel J, Karuranga S, Divakar H. IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's Criteria. Diabetes research and clinical practice. 2022 Jan 1;183:109050.

2. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nature reviews Disease primers. 2019 Jul 11;5(1):47.

3. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England journal of medicine. 2005 Jun 16;352(24):2477-86.

4. Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS, Crowther CA. Effect of treatment of gestational diabetes mellitus on obesity in the next generation. Diabetes care. 2010 May 1;33(5):964-8.

5. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp Jr JM, Sciscione A. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine. 2009 Oct 1;361(14):1339-48.

6. Landon MB, Rice MM, Varner MW, Casey BM, Reddy UM, Wapner RJ, Rouse DJ, Biggio JR Jr, Thorp JM, Chien EK, Saade G, Peaceman AM, Blackwell SC, VanDorsten JP; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network. Mild gestational diabetes mellitus and long-term child health. Diabetes Care. 2015 Mar;38(3):445-52. doi: 10.2337/dc14-2159. Epub 2014 Nov 20. PMID: 25414152; PMCID: PMC4338507.

7. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. American journal of obstetrics and gynecology. 1999 Apr 1;180(4):903-16.

8. Gunderson EP, Quesenberry Jr CP, Jacobs Jr DR, Feng J, Lewis CE, Sidney S. Longitudinal study of pre-pregnancy cardiometabolic risk factors and subsequent risk of gestational diabetes mellitus: the CARDIA study. American journal of epidemiology. 2010 Nov 15;172(10):1131-43.

9. Alwash S, McIntyre D, Mamun A. The pre-pregnancy fasting blood glucose, glycated hemoglobin and lipid profiles as blood biomarkers for gestational diabetes mellitus: evidence from a multigenerational cohort study. The Journal of Maternal-Fetal & Neonatal Medicine. 2023 Dec 31;36(1):2195524.

10. Harville EW, Viikari JS, Raitakari OT. Preconception cardiovascular risk factors and pregnancy outcome. Epidemiology 2011;22:724–730

11. Retnakaran R, Shah BR. Divergent trajectories of cardiovascular risk factors in the years before pregnancy in women with and without gestational diabetes mellitus: a population-based study. Diabetes Care. 2020 Oct 1;43(10):2500-8.

12. Yajnik CS, Bandopadhyay S, Bhalerao A, Bhat DS, Phatak SB, Wagh RH, Yajnik PC, Pandit A, Bhave S, Coyaji K, Kumaran K. Poor in utero growth, and reduced β-cell compensation and high fasting glucose from childhood, are harbingers of glucose intolerance in young Indians. Diabetes Care. 2021 Dec 1;44(12):2747-57.

13. D'Souza N, Behere RV, Patni B, Deshpande M, Bhat D, Bhalerao A, Sonawane S, Shah R, Ladkat R, Yajnik P, Bandyopadhyay SK. Pre-conceptional Maternal Vitamin B12 Supplementation Improves Neurodevelopment at 2 Offspring Years of Age: PRIYA Trial. Nutrition During the First 1000 Days and Fetal Programming. 2022 Aug 16; 9:755977.

14. WHO Study Group on Diabetes Mellitus. Diabetes mellitus: report of a WHO study group. World Health Organization; technical report series, 1985; (727):9-17.

15. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et. al., The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine, 2008; 358(19), pp. 1991–2002. doi:10.1056/nejmoa0707943.

16. Han ES, Krauss RM, Xu F, Sridhar SB, Ferrara A, Quesenberry CP, Hedderson MM. Prepregnancy adverse lipid profile and subsequent risk of gestational diabetes. The Journal of Clinical Endocrinology & Metabolism. 2016 Jul 1;101(7):2721-7.

17. Saravanan P, Deepa M, Ahmed Z, Ram U, Surapaneni T, Kallur SD, Desari P, Suresh S, Anjana RM, Hannah W, Shivashri C. Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts. The Lancet Diabetes & Endocrinology. 2024 Aug 1;12(8):535-44.

18. Retnakaran R, Shah BR. Impact of pregnancy on the trajectories of cardiovascular risk factors in women with and without gestational diabetes. Diabetes, Obesity and Metabolism. 2021 Oct;23(10):2364-73.

19. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Kieltyka L, Berenson GS. Utility of childhood glucose homeostasis variables in predicting adult diabetes and related cardiometabolic risk factors: the Bogalusa Heart Study. Diabetes Care 2010; 33:670–675

20. Jeffery AN, Metcalf BS, Hosking J, Streeter AJ, Voss LD, Wilkin TJ. Age before stage: insulin resistance rises before the onset of puberty: a 9-year longitudinal study (EarlyBird 26). Diabetes Care 2012;35:536–541

21. Hu T, Jacobs DR Jr, Sinaiko AR, et al. Childhood BMI and fasting glucose and insulin predict adult type 2 diabetes: the International Childhood Cardiovascular Cohort (i3C) Consortium. Diabetes Care 2020;43:2821–2829.

22. Powe CE. Early pregnancy biochemical predictors of gestational diabetes mellitus. Current diabetes reports. 2017 Feb;17:1-10.

23. Griffith RJ, Alsweiler J, Moore AE, Brown S, Middleton P, Shepherd E, Crowther CA. Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews. 2020(6).

24. Quotah OF, Andreeva D, Nowak KG, Dalrymple KV, Almubarak A, Patel A, Vyas N, Cakir GS, Heslehurst N, Bell Z, Poston L. Interventions in preconception and pregnant women at risk of gestational diabetes; a systematic review and meta-analysis of randomised controlled trials. Diabetology & Metabolic Syndrome. 2024 Jan 4;16(1):8.

25. Takele WW, Vesco KK, Josefson J, Redman LM, Hannah W, Bonham MP, Chen M, Chivers SC, Fawcett AJ, Grieger JA, Habibi N. Effective interventions in preventing gestational diabetes mellitus: A systematic review and meta-analysis. Communications medicine. 2024 Apr 20;4(1):75.

26. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, Barker M, Saffery R, Yajnik CS, Eckert JJ, Hanson MA. Origins of lifetime health around the time of conception: causes and consequences. The Lancet. 2018 May 5;391(10132):1842-52.
27. Chen B, Du YR, Zhu H, Sun ML, Wang C, Cheng Y, Pang H, Ding G, Gao J, Tan Y, Tong X. Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency. Nature. 2022 May 26;605(7911):761-6.
28. Rönn T, Perfilyev A, Oskolkov N, Ling C. Predicting type 2 diabetes via machine learning integration of multiple omics from human pancreatic islets. Scientific Reports. 2024 Jun 25;14(1):14637
29. Vicente C. An interview with Lewis Wolpert. Development. 2015 Aug 1;142(15):2547-8.
30. Stephenson J, Heslehurst N, Hall J, Schoenaker DA, Hutchinson J, Cade JE, Poston L, Barrett G, Crozier SR, Barker M, Kumaran K. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. The Lancet. 2018 May 5;391(10132):1830-41.
31. Rose G. Sick individuals and sick populations. International journal of epidemiology. 2001 Jun 1;30(3):427-32.
32. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002 Jul 20;325(7356):157-60.
33. Jarrett RJ. Gestational diabetes. Diabetic Medicine: a Journal of the British Diabetic Association. 1994 Dec 1;11(10):992-3.
34. Harris MI. Gestational diabetes may represent discovery of preexisting glucose intolerance. Diabetes care. 1988 May 1;11(5):402-11.
35. Simmons D, Hague WM, Teede HJ, Cheung NW, Hibbert EJ, Nolan CJ, Peek MJ, Girosi F, Cowell CT, Wong VW, Flack JR. Hyperglycaemia in early pregnancy: the Treatment of Booking Gestational diabetes Mellitus (TOBOGM) study. A randomised controlled trial. Medical Journal of Australia. 2018 Nov;209(9):405-6.

Acknowledgements

We thank the participants, collaborators, funding agencies, and the Diabetes Unit staff for their contribution towards this study.

Authors' contributions

CY and CF conceptualized the study. SB, RW and CO were involved in statistical analysis. KJC, PY, RL contributed to conduct of the study. CY, CF, and RW prepared the manuscript. DB was involved in laboratory measurements.

Declaration of interests:

All the authors declare no conflicts of interest.

Data sharing statement:

Data is available with Prof C S Yajnik for sharing to confirm our findings and for additional analyses by applying to the corresponding author with a 200-word plan of analysis. Data sharing is subject to KEMHRC Ethics Committee approval and Government of India's Health Ministry advisory committee permission.

Table 1: Comparison of biomarkers between F1 participants with normoglycemia and fasting hyperglycemia in pregnancy (based on quartiles of FPG at 28 weeks of gestation)

		F1 WOMEN			
	Gestational normoglycemia (median)	Gestational fasting hyperglycemia (median)	Difference (Z-score) Fasting hyperglycemic - normoglycemic		p
			Mean	(95% CI)	
F0 generation					
Mother	**N=108**	**N=35**			
Fasting plasma glucose at 28wk gestation	3.9	3.9	0.08	-0.32, 0.47	0.708
2h plasma glucose at 28wk gestation	4.2	4.3	-0.09	-0.58, 0.39	0.703
Ever-glucose intolerant (postnatal)	**48 (37.8%)**	**24 (54.5%)**	**..**	**..**	**0.039**
Ever-overweight/obese	10 (7.9%)	7 (15.9%)	..	..	0.110
F1 generation					
BIRTH	**N=125**	**N=44**			
Gestation (weeks)	39.1	38.7	-0.08	-0.63, 0.46	0.768
Weight (g)	2600	2500	-0.07	-0.43, 0.29	0.708
Length (cm)	47.4	47.7	-0.01	-0.36, 0.34	0.964
2 YEARS	**N=115**	**N=38**			
Height (cm)	**80.7**	**81.8**	**0.41**	**0.05, 0.79**	**0.026**
Weight (kg)	**9.10**	**9.70**	**0.43**	**0.06, 0.79**	**0.022**
6 YEARS	**N=126**	**N=44**			
Height (cm)	**108.8**	**110.6**	**0.34**	**0.00, 0.67**	**0.051**
BMI (kg/m^2)	12.9	13.37	0.32	-0.03, 0.67	0.072
Waist circumference (cm)	**49.5**	**50.4**	**0.42**	**0.07, 0.76**	**0.017**
Fasting glucose (mmol/l)	**4.7**	**5.1**	**0.42**	**0.08, 0.77**	**0.017**
30-min glucose (mmol/l)	8.3	8.5	0.06	-0.30, 0.42	0.739
120-min glucose (mmol/l)	5.6	5.7	0.23	-0.11, 0.58	0.183

		F1 WOMEN			
		Gestational normoglycemia (median)	Gestational fasting hyperglycemia (median)	Difference (Z-score) Fasting hyperglycemic - normoglycemic		p
				Mean	(95% CI)	
12 YEARS		**N=125**	**N=44**			
Height (cm)		139.3	142.1	0.21	-0.12, 0.55	0.214
BMI (kg/m^2)		**14.2**	**14.7**	**0.42**	**0.07, 0.77**	**0.018**
Waist circumference (cm)		**55.5**	**56.3**	**0.35**	**0.00, 0.70**	**0.049**
Fasting glucose (mmol/l)		**4.6**	**4.8**	**0.38**	**0.04, 0.71**	**0.029**
		N=70	**N=27**			
HbA1c (%) at 15-years n=97		5.3	5.5	0.40	-0.04, 0.83	0.072
		N=119	**N=42**			
HbA1c (%) at 17-years n=161		5.3	5.3	0.32	-0.02, 0.66	0.064
18 YEARS		**N=120**	**N=42**			
Height (cm)		156.8	158.5	0.20	-0.15, 0.54	0.258
BMI (kg/m^2)		**17.9**	**19.1**	**0.46**	**0.11, 0.81**	**0.011**
Underweight		**76 (63.3)**	**15 (35.7)**	**..**	**..**	**0.046**
Overweight/obese		**4 (3.3)**	**3 (7.1)**	**..**	**..**	**0.046**
Waist circumference (cm)		**66.1**	**68.8**	**0.47**	**0.13, 0.82**	**0.008**
Central obesity, >=80 N(%)		**4 (3.3)**	**3 (7.1)**	**..**	**..**	**0.298**
Fasting glucose (mmol/l)		**5.1**	**5.2**	**0.49**	**0.14, 0.83**	**0.006**
30-min glucose (mmol/l)		8.3	8.6	0.24	-0.13, 0.61	0.206
120-min glucose (mmol/l)		6.3	6.3	-0.02	-0.40, 0.35	0.906
Glucose intolerance (IFG+IGT+DM)		**23 (22.5)**	**11 (27.5)**	**..**	**..**	0.535
28 WEEKS' GESTATION IN PREGNANCY		**N=127**	**N=44**			
Height (cm)		157.0	158.2	0.14	-0.21, 0.48	0.441
BMI (kg/m^2)		**21.3**	**23.3**	**0.52**	**0.19, 0.86**	**0.003**
Gestational weight gain (GWG, kg)		8.9	8.9	0.29	-0.06, 0.65	0.100

		F1 WOMEN			
		Gestational normoglycemia (median)	**Gestational fasting hyperglycemia** (median)	**Difference (Z-score) Fasting hyperglycemic - normoglycemic**	**p**
				Mean | **(95% CI)**	
Fasting glucose (mmol/l)		**4.3**	**4.9**	**1.63** | **1.39, 1.87**	**<0.001**
60-min glucose (mmol/l)		**7.5**	**7.9**	**0.37** | **0.02, 0.72**	**0.037**
120-min glucose (mmol/l)		**6.2**	**6.6**	**0.42** | **0.06, 0.78**	**0.021**
24 YEARS (POST-DELIVERY)		**N=103**	**N=33**		
Height (cm)		156.75	158	0.21 | -0.14 , 0.57	0.237
BMI (kg/m^2)		**20.5**	**23.8**	**0.65** | **0.23 , 1.07**	**0.003**
Overweight/obese N(%)		**17 (16.5)**	**15 (45.4)**	**..** | **..**	**0.003**
Waist circumference (cm)		**72.0**	**78.7**	**0.76** | **0.33 , 1.19**	**0.001**
Central obesity, >=80, N(%)		**21 (23.3)**	**18 (60)**	**..** | **..**	**<0.001**
Fasting glucose (mmol/l)		**4.9**	**5.3**	**0.77** | **0.36 , 1.18**	**<0.001**
30-min glucose (mmol/l)		**7.9**	**8.8**	**0.66** | **0.30 , 1.02**	**<0.001**
120-min glucose (mmol/l)		5.7	6.3	0.36 | -0.06 , 0.78	0.095
Glucose intolerance (IFG+IGT+DM)		**9 (8.7)**	**13 (38.2)**	**..** | **..**	**<0.001**
F2 generation		**N=126**	**N=43**		
Male % *		51.6	58.1	.. | ..	0.458
Birthweight (g)		2753	2780	**..** | **..**	**..**
Birthweight Z-scores (Intergrowth)		-1.3	-0.8	0.35 | -0.07, 0.77	0.104

Data presented as median. p-value calculated by t-test or chi-square test as appropriate

Figure 1: The Pune Maternal Nutrition Study.

Figure shows the design and progress of the preconceptional birth cohort Pune Maternal Nutrition Study from 1993 to 2024. Pregnancies were studied in F0 mothers to investigate determinants of fetal growth, F1 were born. F1 and F0 have been serially followed up for various cardio-metabolic markers as shown in the boxes. F1 adolescents participated in a vit B12 and multi-micronutrient primordial trial to promote fetal growth and reduce risk of diabesity in the F2 offspring. F1 pregnancies were studied for maternal nutritional and metabolic measurements. This paper traces glucose metabolism in F1 participants from their intrauterine life, through childhood, puberty, adulthood and into pregnancy.

Figure 2: Life course evolution of anthropometry and fasting glucose concentration in participants with gestational fasting hyperglycemia and normoglycemia.

The figure shows serial anthropometry (a, b, c) and fasting glucose (d) in participants with normoglycemia (blue) and fasting hyperglycemia (red). The points represent median values, significant differences between the two groups ($P< 0.05$) are indicated by an asterisk.

Figure 3: Prevalence of hyperglycemia by quartiles of early life glycemia.

(a-c) Prevalence of fasting hyperglycemia at 28 weeks of gestation by quartiles of fasting glucose at 6y, 12y and 18y of age; (d) prevalence of glucose intolerance (prediabetes + diabetes, ADA criteria) at 24y by quartiles of FPG at 28-wk gestation.

Figure 4: Forest plots representing risk of gestational fasting hyperglycemia and post-pregnancy glucose intolerance by quartiles of early life fasting glucose measurements.

Odds ratios for risk of fasting hyperglycemia (Q4) at 28 weeks of gestation for the highest quartile (Q4) of fasting glucose at 6y, 12y and 18y against (Q1+2+3); and of glucose intolerance at 24-year (ADA criteria) for highest quartile (Q4) of fasting glucose at 6y, 12y and 18y, and 28-wks gestation.

Figure 1: The Pune Maternal Nutrition Study. Figure shows the design and progress of the preconceptional birth cohort Pune Maternal Nutrition Study from 1993 to 2024. Pregnancies were studied in F0 mothers to investigate determinants of fetal growth, F1 were born. F1 and F0 have been serially followed up for various cardio-metabolic markers as shown in the boxes. F1 adolescents participated in a vit B12 and multi-micronutrient primordial trial to promote fetal growth and reduce risk of diabesity in the F2 offspring. F1 pregnancies were studied for maternal nutritional and metabolic measurements. This paper traces glucose metabolism in F1 participants from their intrauterine life, through childhood, puberty, adulthood and into pregnancy.

Figure 2: Life course evolution of anthropometry and fasting glucose concentration in participants with gestational fasting hyperglycemia and normoglycemia. The figure shows serial anthropometry (a, b, c) and fasting glucose (d) in participants with normoglycemia (blue) and fasting hyperglycemia (red). The points represent median values, significant differences between the two groups (P< 0.05) are indicated by an asterisk.

Figure 3: Prevalence of hyperglycemia by quartiles of early life glycemia. (a-c) Prevalence of fasting hyperglycemia at 28 weeks of gestation by quartiles of fasting glucose at 6y, 12y and 18y of age; (d) prevalence of glucose intolerance (prediabetes + diabetes, ADA criteria) at 24y by quartiles of FPG at 28-wk gestation.

Figure 4: Forest plots representing risk of gestational fasting hyperglycemia and post-pregnancy glucose intolerance by quartiles of early life fasting glucose measurements. Odds ratios for risk of fasting hyperglycemia (Q4) at 28 weeks of gestation for the highest quartile (Q4) of fasting glucose at 6y, 12y and 18y against (Q1+2+3); and of glucose intolerance at 24-year (ADA criteria) for highest quartile (Q4) of fasting glucose at 6y, 12y and 18y, and 28-wks gestation.